Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Receives CE Mark for ALTO Abdominal Stent Graft System

Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S. commercial release

Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

Endologix Appoints Tim A. Benner as Chief Commercial Officer

Endologix Adds Jane E. Kiernan to its Board of Directors